Companies › Cantex Pharmaceuticals
1 active drug program in 4 registered trials: 2 Phase 2, 2 Phase 1; Infectious disease, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Azeliragon Advanced glycosylation end product-specific receptor antagonist | AGER | Phase 2 | Glioblastoma; COVID-19; Cancer Related Cognitive Decline; Solid Tumor | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05815485 | Azeliragon | Phase 2 | COVID-19 | Infectious disease | Apr 2026 |
| NCT05256745 | Azeliragon | Phase 1 | Cancer Related Cognitive Decline | Oncology | Dec 2026 |
| NCT05986851 | Azeliragon | Phase 2 | Glioblastoma | Oncology | Dec 2026 |
| NCT06724926 | Azeliragon | Phase 1 | Solid Tumor | Oncology | Jan 2027 |
Tetraphase Pharmaceuticals Amivas The Skin Center Dermatology Group Shanghai Jiatan Pharmatech Shanghai Guangsheng Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.